STARTUP PROFILE

Salvia BioElectronics

COUNTRY
Netherlands
FOUNDED
2017
CATEGORY
Neuromodulation
Developing an implantable neuromodulation system to treat chronic migraine by modulating neural pathways involved in pain processing.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Series B
MODALITY
Nerve stimulator
FORM FACTOR
Implant
INTERFACE DEPTH
Minimally invasive
INDICATION
Pain/migraine
TARGET USER
Patients
REGULATORY STAGE
Investigational
Salvia BioElectronics is one of the more visible migraine neuromodulation startups, using implantable systems to modulate headache-related pathways. Its positioning is attractive because migraine is a large market with poor options for many patients, though it remains investigational.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
12
NVIDIA and OpenAI invest in neurotech
13 October – 27 October 2026

Salvia BioElectronics treated its first US patient in RECLAIM-II, a pivotal randomized, double-blind trial of its MySalvia system for resistant migraine. The system uses two ultra-thin implants placed beneath the skin at the front and back of the head, activated twice daily using a wearable device. The study aims to enroll around 150 patients across more than 20 US sites.

Articles featuring
Salvia BioElectronics